SAB Biotherapeutics (NasdaqCM:SABS) FY Conference Transcript

Summary of SAB Biotherapeutics FY Conference Call Company Overview - Company: SAB Biotherapeutics (NasdaqCM:SABS) - Industry: Clinical-stage biotechnology - Lead Asset: Human anti-thymocyte immunoglobulin for treating newly diagnosed type 1 diabetes patients - Current Phase: Entering phase 2b clinical trial, considered pivotal with expectations of being a best-in-class product [2][4][12] Core Product Insights - Comparison with Rabbit ATG: - Rabbit anti-thymocyte globulin (ATG) is the global standard for organ transplant but has safety issues (serum sickness) and cannot be redosed due to immunogenicity [4][10] - SAB's product aims to preserve C-peptide and reduce HbA1c without the adverse effects associated with rabbit ATG [4][10] - MELD Study Findings: - Conducted in Europe, showed that a lower dose (0.5 mg/kg) of rabbit ATG was effective without lymphodepletion, decoupling efficacy from lymphodepletion [9][10] - Confirms that the mechanism of action for both rabbit ATG and SAB's product leads to C-peptide preservation and HbA1c reduction [10][11] Regulatory Landscape - FDA Insights: - The FDA is increasingly open to approving drugs based on C-peptide preservation alone, as demonstrated by the trajectory of Tzield, which was acquired by Sanofi [13][15] - The approval of Tzield indicates a clearer path for SAB's product, as it suggests that C-peptide is a sufficient endpoint for approval [15][16] Clinical Trial Design - SAFEGUARD Study: - The study will be stratified by age groups (adults, adolescents, children) to ensure a balanced representation [17][18] - C-peptide levels will be a primary endpoint, with a baseline requirement of 200 picomole per liter [32][34] - The study aims for an 80% power to show a difference in HbA1c [35] - Future Trials: - Plans for a confirmatory trial in Stage 2 patients, focusing on early intervention to preserve insulin production [36][39] Market Opportunity - Unmet Medical Need: - There is a significant demand for therapies in type 1 diabetes, with 65,000 new patients diagnosed annually and no approved drug currently available [43][44] - The ability to preserve beta cell mass could drastically improve patient outcomes and quality of life, addressing a major burden of disease management [42][44] - Commercial Potential: - The product is expected to fill a critical gap in treatment options for type 1 diabetes, which is currently managed through insulin and glucose monitoring without altering long-term outcomes [42][44] Additional Considerations - Patient Impact: - The emotional and social burden of managing type 1 diabetes is significant, and the introduction of a drug that preserves insulin production could alleviate some of these challenges [42][44] - Community Engagement: - Emphasis on understanding patient experiences and needs through direct engagement with the diabetes community [44]